Kisameet Glacial Clay
About Kisameet Glacial Clay Inc.
Incorporated in 2006 to revisit the curative uses of a mineral clay by the Indigenous people of the central coast of Western Canada. The mineral clay has been known to science since the 1930’s, when famed Colloid Scientist Dr. Ernst Hauser, Professor of Chemistry at MIT, published multiple Papers citing the uniqueness of the mineral clay in composition, size and particle shape.
Kisameet Glacial Clay initiated further research studies which took place at UBC from 2011 to 2016, and which resulted in breakthroughs in research by Dr. Julian Davies.
Going forward, Kisameet Glacial Clay Inc. is responsible for the production of Kisolite for exclusive sale by its subsidiary, Kisolite Corp.
Kisameet Glacial Clay Inc. has production operations in Squamish and at Kisameet Bay, and head office in Smithers, BC. The company operates seasonally on the coast to support year-round supply chain services.
The Founders of Kisameet Glacial Clay Inc. are Lawrence Lund, Doug Frankiw and Rowland Hanson. Following the publication in mBio by researchers from UBC, the following editorial was published in the Journal of the Microsoft Alumni Association by Rowland Hanson.
A Glacial Clay Used By Indigenous People of Western Canada for Decades Could Be The Solution To Antibiotic–Resistant Pathogens
"Almost 2 million Americans per year develop hospital-acquired infections resulting in 99,000 deaths, the vast majority of which are due to antibiotic-resistant pathogens.
My involvement at the Microsoft Alumni Network provides insight into many pressing health issues the global community faces, none greater than disease associated with the growing trend of antibiotic resistance. A few years ago the U.S. Centers for Disease Control and Prevention (CDC) published a report that highlighted in just one organism alone, methicillin resistant staphylococcus aureus (MRSA), killed more Americans, (19,000) than emphysema, HIV/AIDS, Parkinson’s disease, and homicide combined. Almost 2 million Americans per year develop hospital-acquired infections (HAI’s), resulting in 99,000 deaths, the vast majority of which are due to antibiotic-resistant pathogens. Indeed, in a single year, two common HAI’s alone (sepsis and pneumonia) killed nearly 50,000 Americans and was estimated to cost the U.S. healthcare system more than $8 billion.
In a recent survey, approximately half of patients in more than 1,000 intensive care units in 75 countries suffered from an infection, and these infected patients had twice the risk of dying in the hospital as uninfected patients. Based on studies of the costs of infections caused by antibiotic-resistant pathogens, the annual costs to the U.S. health care system and society of antibiotic-resistant infections is $21 billion and more than 8 million additional hospital days. Antimicrobial resistance was recently recognized as one of the greatest threats to human health on the planet. For that reason, the World Health Organization (WHO) proclaimed antimicrobial resistance the focus of a World Health Day back on April 7, 2011.
Near the same date in early 2011 I met two entrepreneurs in Vancouver who were thinking about starting a company to commercialize “glacial clay” by creating a line of skin care products. My pre-Microsoft experience as Vice President of Global Marketing for Neutrogena gave me the ability to appreciate their vision. Soon Lawry Lund, Doug Frankiw and I became partners. Within months we incorporated Kisameet Glacial Clay. Collectively we were enthusiastic about the financial prospects for a skin care line based on glacial clay. For many years various sources of clay have been the basis of popular skin care lines.
However, our commercialization plans were interrupted when we discovered a collection of research from the Massachusetts Institute of Technology originating in the late 1940’s and 1950’s. This research suggested that Kisameet clay might have antibiotic properties and that was the reason the Indigenous people of the area had been using the clay for decades for medicinal purposes. With this new insight the company approached researchers at The University of British Columbia to confirm the MIT research that had been conducted over half a century prior.
On January 26th, 2016, essentially five years later, UBC published peer-reviewed research entitled “Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens”.
In hospitals all over the world, ESKAPE is the name given to a small group of bad bugs: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumanni, Pseudomonas aeruginosa, and Enterobacter species."